![]() The FDA cleared it for people with obesity or those characterized as overweight with at least one weight-related health condition, such as high blood pressure or heart disease, the same indication as for Wegovy. Zepbound was shown in clinical trials to yield more than 20% average weight loss on higher doses over 72 weeks, stronger results than seen with other approved medicines. Made by Eli Lilly, it’s part of a new class of drugs that includes semaglutide, known as Ozempic for diabetes and Wegovy for weight loss, which have skyrocketed in popularity in recent years. The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. ![]() George Frey/Reutersīlood sugar drug tirzepatide also leads to substantial weight loss in diabetes patients, Eli Lilly says ![]() ![]() Eli Lilly says tirzepatide, a drug used to treat type 2 diabetes, also leads to substantial weight loss in diabetes patients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |